Atlas Trials

Metastatic Hormone-sensitive Prostate Cancer

28 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Metastatic Hormone-sensitive Prostate Cancer

RecordFirmDate
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (NCT05059236)Bayer2021-11-04
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study (NCT05381311)Astellas Pharma Global Development, Inc.2021-09-03
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension (NCT04934722)Merck Sharp & Dohme LLC2021-05-25
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC. (NCT07428642)First Affiliated Hospital of Wenzhou Medical University2020-09-01
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) (NCT04191096)Merck Sharp & Dohme LLC2020-02-12
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (NCT04076059)Astellas (Beijing) Pharmaceutical R&D Co., Ltd.2019-09-11
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer (NCT03879122)Spanish Oncology Genito-Urinary Group2019-02-11
Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (NCT03343977)Peng Wang, MD PhD2018-02-14
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (NCT02799602)Bayer2016-11-30
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (NCT02677896)Astellas Pharma Global Development, Inc.2016-03-09
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer (NCT00309985)ECOG-ACRIN Cancer Research Group2006-09-26

Track Metastatic Hormone-sensitive Prostate Cancer automatically

Every clearance here is in the API, with alerts when new ones post.